<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04857164</url>
  </required_header>
  <id_info>
    <org_study_id>NCT12345</org_study_id>
    <nct_id>NCT04857164</nct_id>
  </id_info>
  <brief_title>Study of Pembrolizumab Combined With Chemotherapy in the First Line Therapy for R/M HNSCC in China</brief_title>
  <official_title>A Prospective Study of Pembrolizumab Combined With Chemotherapy (Cisplatin or Carboplatin + Albumin-bound Paclitaxel) in First-line Therapy for Patients With Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shi Yuankai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is main evaluate the efficacy and safety of pembrolizumab combined with&#xD;
      chemotherapy in the first-line treatment of Chinese patients with recurrent or metastatic&#xD;
      head and neck squamous cell carcinoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a single-center, prospective phase II clinical study, which mainly evaluates&#xD;
      the efficacy and safety of first-line treatment with pembrolizumab combined with chemotherapy&#xD;
      in patients with recurrent and/or metastatic head and neck squamous cell carcinoma&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>survival time (OS)</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the survival time (OS) of pembrolizumab combined with chemotherapy in the first-line treatment of Chinese patients with recurrent and or metastatic head and neck squamous cell carcinoma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>progression free survival(PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the progression free survival (PFS) of pembrolizumab combined with chemotherapy in the first-line treatment of Chinese patients with recurrent and or metastatic head and neck squamous cell carcinoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate(ORR)</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the objective response rate of pembrolizumab combined with chemotherapy in the first-line treatment of Chinese patients with recurrent and or metastatic head and neck squamous cell carcinoma (ORR, RECIST 1.1 and iRECIST standard evaluation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate (DCR)</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the disease control rate of pembrolizumab combined with chemotherapy in the first-line treatment of Chinese patients with recurrent and or metastatic head and neck squamous cell carcinoma (DCR, RECIST 1.1 and iRECIST standard evaluation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response (DOR)</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the duration of response (DOR) of pembrolizumab combined with chemotherapy in the first-line treatment of Chinese patients with recurrent and or metastatic head and neck squamous cell carcinoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival rate(PFS rate)</measure>
    <time_frame>1 year</time_frame>
    <description>PFS rates at 6 and 12 months</description>
  </secondary_outcome>
  <other_outcome>
    <measure>TMB, T cell gene expression</measure>
    <time_frame>3 year</time_frame>
    <description>Correlation between the results of TMB and inflammatory T cell gene expression profiles in tumor tissues of baseline patients and the efficacy and prognosis.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab combined with Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy regimen* is as follows, selected by the investigator, 3 weeks (21 days) is a cycle，combined with pembrolizumab 200 mg intravenously on day 1, every 21 days is a treatment cycle until the disease progresses or the toxicity cannot be tolerated(Less than or equal to 35 cycle)&#xD;
*1) Cisplatin(75 mg/m2) + albumin-bound paclitaxel(260 mg/m2) 2)Cisplatin(25 mg/m2,d1-d3) + albumin-bound paclitaxel(260 mg/m2) 3)Carboplatin(AUC5) + Albumin-bound Paclitaxel(260 mg/m2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab combined with Chemotherapy</intervention_name>
    <description>Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer Chemotherapy regimen is selected by the investigator immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer.</description>
    <arm_group_label>Pembrolizumab combined with Chemotherapy</arm_group_label>
    <other_name>keytruda and Chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily sign written informed consent before screening;&#xD;
&#xD;
          2. Age 18~75 years old;&#xD;
&#xD;
          3. ECOG physical status score 0-1 points;&#xD;
&#xD;
          4. Head squamous cell carcinoma (HNSCC) diagnosed by histology or cytology, the primary&#xD;
             site is oral cavity, oral cavity Throat, lower throat or throat;&#xD;
&#xD;
          5. Recurrent and/or metastatic HNSCC without indications for local radical treatment;&#xD;
&#xD;
          6. According to the evaluation criteria for the efficacy of solid tumors (RECIST version&#xD;
             1.1), there is at least one measurable lesion, right For lesions that have received&#xD;
             radiotherapy in the past, only if there is clear disease progression 3 months after&#xD;
             the end of radiotherapy, can it be Was selected as the target lesion;&#xD;
&#xD;
          7. There are a large number of tumor tissue samples for PD-L1 immunohistochemical&#xD;
             detection;&#xD;
&#xD;
          8. The expected survival period exceeds 3 months;&#xD;
&#xD;
          9. The main organs function normally, that is, they meet the following standards:&#xD;
&#xD;
             I. Blood routine (not receiving blood transfusion 14 months before screening&#xD;
             examination, erythropoietin (EPO), granulocyte set Fall stimulating factor (G-CSF) or&#xD;
             granulocyte-macrophage colony stimulating factor (GM-CSF) treatment): neutral&#xD;
             Granulocyte ≥1.5×l09&#xD;
&#xD;
               -  L, platelets ≥100×109&#xD;
&#xD;
               -  L, hemoglobin≥90g/L; ii. Liver function: alanine aminotransferase (ALT) and&#xD;
                  aspartate aminotransferase (AST), ALT and AST ≤ 3 for those without liver&#xD;
                  metastasis ×ULN, ALT and AST for liver metastases≤5×ULN; total bilirubin&#xD;
                  (TBIL)≤1.5×ULN (Gilbert Syndrome patients, ≤3×ULN); iii. Renal function: Serum&#xD;
                  creatinine (Cr)≤1.5×ULN or tendon clearance (Ccr)≥50ml/min (connect Residues&#xD;
                  treated with carboplatin) or ≥60ml/min (residuals treated with cisplatin); iv.&#xD;
                  Coagulation function: activated partial thromboplastin time (APTT), international&#xD;
                  normalized ratio (INR), thrombin Original time (PT)≤1.5×ULN; v. Heart&#xD;
                  echocardiogram: left ventricular ejection fraction (LVEF) ≥50%;&#xD;
&#xD;
         10. Women should agree to use contraceptive measures (such as intrauterine birth control)&#xD;
             during the study period and within 6 months after the study ends.&#xD;
&#xD;
        Device [IUD], contraceptive pill or condom); 7 diabetes blood pregnancy test was negative&#xD;
        before study enrollment, and it must be non-Breastfeeding patients; males should agree to&#xD;
        use contraceptive measures during the study period and within 6 months after the end of the&#xD;
        study period patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are suitable for local treatment and are willing to local treatment;&#xD;
&#xD;
          2. Have received systemic chemotherapy, but does not include treatment for locally&#xD;
             advanced disease as a part of multimodal treatment Chemotherapy (the end of this&#xD;
             treatment must be more than 6 months after the first trial medication); Note:&#xD;
             Multimodal therapy includes induction chemotherapy, concurrent radiotherapy and&#xD;
             chemotherapy and adjuvant chemotherapy.&#xD;
&#xD;
          3. Locally advanced head and neck squamous cell carcinoma multimodal treatment is&#xD;
             completed within 6 months of disease progression;&#xD;
&#xD;
          4. Have received anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti-CTLA-4 antibodies&#xD;
             or targeting effects in the past Any other antibody or drug immunotherapy in T cell&#xD;
             co-stimulation or immune checkpoint pathway;&#xD;
&#xD;
          5. Other malignant tumors have occurred within 5 years or at the same time during the&#xD;
             current period, except for cured cervical carcinoma in situ, non- Skin cancer of&#xD;
             melanoma or other tumors/cancers that have undergone radical treatment and have no&#xD;
             signs of disease for at least 5 years;&#xD;
&#xD;
          6. Received cetuximab treatment within 6 months before the first administration;&#xD;
&#xD;
          7. According to the standard of common adverse event term (NCI CTCAEv5.0), peripheral&#xD;
             neuropathy has been ≥2 grade;&#xD;
&#xD;
          8. With known active central nervous system metastasis (CNS) and/or cancerous meningitis:&#xD;
             previous treatment Subjects with brain metastases treated for treatment can&#xD;
             participate in the study, provided that they are clinically stable for at least 2&#xD;
             weeks and there are no new or enlarged brains.&#xD;
&#xD;
             Evidence was transferred, and steroids were discontinued 14 days before study drug&#xD;
             administration. The stable brain metastasis in this definition should be in Determine&#xD;
             before the first administration of the study drug. Subjects with asymptomatic brain&#xD;
             metastases (ie no neurological symptoms, no need Corticosteroids, and no lesions&gt;&#xD;
             1.5cm) can participate, but the brain needs to be regularly performed as a disease&#xD;
             site Film degree exam;&#xD;
&#xD;
          9. Did not recover from any acute effects of previous surgery, chemotherapy or&#xD;
             radiotherapy, that is, did not fall to ≤1 grade (NCI CTCAEv5.0) subjects (except for&#xD;
             hair loss). If the nutritional status is stable, allow previous radiotherapy and/or&#xD;
             surgery Chronic late toxicity (pharyngeal/larynx toxicity, ie dry mouth, abnormal&#xD;
             speech, swallowing, etc.);&#xD;
&#xD;
         10. Any component of the studied drug or preparation has caused severe allergic reactions,&#xD;
             including known Severe allergic reaction to Longan antibody (NCI CTCAEv5.0≥3);&#xD;
&#xD;
         11. Have received anti-tumor drug treatment (such as chemotherapy, hormone therapy, immune&#xD;
             Disease treatment, antibody treatment, radiotherapy, etc.), except for palliative&#xD;
             radiotherapy for bones to relieve pain;&#xD;
&#xD;
         12. Chinese herbal medicine or Chinese patent medicine receiving anti-tumor treatment ≤1&#xD;
             week before the first administration;&#xD;
&#xD;
         13. Have received major surgery within 4 weeks before the first administration or are&#xD;
             expected to undergo major surgery during the study period;&#xD;
&#xD;
         14. Immunosuppressive drugs need to be used 2 weeks before the first administration or&#xD;
             within 2 weeks or during the study period. The following conditions are excluded:&#xD;
&#xD;
               1. Intranasal, inhaled, topical steroid or topical steroid injection (such as&#xD;
                  intra-articular injection);&#xD;
&#xD;
               2. Physiological dose of systemic corticosteroids (≤10mg/day prednisone or&#xD;
                  equivalent dose);&#xD;
&#xD;
               3. Short-term (≤7 days) use of steroids to prevent or treat non-autoimmune allergic&#xD;
                  diseases;&#xD;
&#xD;
         15. Subjects who are known to have active or have a history of autoimmune diseases that&#xD;
             are likely to relapse (such as:&#xD;
&#xD;
             Systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease,&#xD;
             autoimmune thyroid disease, multiple Sexual sclerosis, vasculitis, glomerulitis,&#xD;
             etc.), or high risk (such as receiving an organ transplant and requiring&#xD;
             immunotherapy) Of patients. However, the following patients are allowed to join the&#xD;
             group: patients with type I diabetes who are in stable condition after using a fixed&#xD;
             dose of insulin Those; autoimmune hypothyroidism requiring only hormone replacement&#xD;
             therapy; no need for systemic therapy Skin diseases (such as eczema, skin rashes that&#xD;
             account for less than 10% of the body surface, psoriasis without ophthalmological&#xD;
             symptoms, etc.);&#xD;
&#xD;
         16. Subjects with known history of interstitial lung disease, history of non-infectious&#xD;
             pneumonia, or high suspicion of interstitial lung disease Those who have previously&#xD;
             had drug-induced or radiation non-infectious pneumonia but asymptomatic subjects are&#xD;
             allowed to enter the group;&#xD;
&#xD;
         17. A history of human immunodeficiency virus infection (positive HIV test), or other&#xD;
             acquired or congenital Immunodeficiency disease, or history of organ transplantation,&#xD;
             or history of stem cell transplantation;&#xD;
&#xD;
         18. The hepatitis B or C virological examination at the time of screening meets any of the&#xD;
             following:&#xD;
&#xD;
               1. HBsAg positive, and peripheral blood hepatitis B virus deoxyribonucleic acid (HBV&#xD;
                  DNA) titer ≥104 Copy number/ml or ≥2000 IU/ml;&#xD;
&#xD;
               2. HCV antibody is positive, and HCV-RNA is higher than the detection limit of the&#xD;
                  analysis method;&#xD;
&#xD;
         19. Within 2 weeks or 2 weeks before the first administration, the subject has an active&#xD;
             infection that requires systemic treatment or is uncontrollable Infection (except for&#xD;
             simple urinary tract infection or upper respiratory tract infection);&#xD;
&#xD;
         20. Live virus vaccine was vaccinated within 4 weeks before the first dose. Allows&#xD;
             vaccination against seasonal influenza that does not contain live viruses seedling;&#xD;
&#xD;
         21. Serous effusions (such as pleural effusions and pleural effusions) with clinical&#xD;
             symptoms that require clinical intervention or stable time less than 4 weeks ascites);&#xD;
&#xD;
         22. Known to be accompanied by serious medical diseases, such as heart function&#xD;
             abnormalities of grade III and above (New York Heart Association [NYHA]),&#xD;
             cardiovascular diseases such as ischemic heart disease (such as myocardial infarction&#xD;
             or angina pectoris), or before the first administration 3 A history of myocardial&#xD;
             infarction within months, and poorly controlled diabetes (fasting blood glucose ≥&#xD;
             10mmol/L) or poorly controlled hypertension (systolic blood pressure ≥160mmHg and/or&#xD;
             diastolic blood pressure ≥100mmHg);&#xD;
&#xD;
         23. Medical or psychiatric history or laboratory abnormal history that may interfere with&#xD;
             the interpretation of results;&#xD;
&#xD;
         24. The subject is currently enrolled in other research equipment or research drug&#xD;
             research, or is away from other research drugs Or the study device is out of use for&#xD;
             less than or equal to 4 weeks;&#xD;
&#xD;
         25. The subject is known to be addicted to alcohol or drugs;&#xD;
&#xD;
         26. The researcher believes that the subjects have other conditions that may affect their&#xD;
             compliance with the protocol and the evaluation of research indicators.&#xD;
&#xD;
        Circumstances, subjects who are not suitable to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuankai Shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute/Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuankai Shi, MD</last_name>
    <phone>+86-10-87788293</phone>
    <email>syuankaipumc@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuankai Shi, MD</last_name>
      <phone>+86-10-87788293</phone>
      <email>syuankaipumc@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Shi Yuankai</investigator_full_name>
    <investigator_title>Director, Head of Oncology, Chief physician</investigator_title>
  </responsible_party>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>immune therapy</keyword>
  <keyword>Pembrolizumab combined with chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

